- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03887065
Magnetic Resonance Imaging Study of JM-4 in Multiple Sclerosis/Clinically Patients
May 5, 2019 updated by: Stuart Cook, MD, Cook, Stuart, MD
Magnetic Resonance Imaging 12 Day Study for Multiple Sclerosis/Clinically Isolated Syndrome Trial of JM-4 Novel Human Peptide
This is a Phase 0/1 study of MS patients to determine the safety and potential efficacy of a novel, small human peptide designated as JM-4.
The study will involve treatment for 5-7 days with JM-4 to determine the effects of Gadolinium(+) lesion number and volume in the brains of patients.
Study Overview
Detailed Description
This study is the first study of JM-4 in patients with Multiple Sclerosis and is intended to show safety and potential efficacy in changing the size and/or number of GAD(+) lesions in the brain.
The initial dose level of 1 mg/kg/ will establish safety of JM-4 treatment after 5-7 days of treatment via intravenous infusion over 30 minutes daily in3-5 patients with Multiple Sclerosis.
MRI examinations will be conducted prior to treatment with JM-4 and 8 days after the initiation of treatment for the purpose of quantitating GAD(+) brain lesions.
Once initial safety is established, the next group of 3-5 patients will receive 4 mg/kg/ of JM-4 daily for 5-7 days via 30 minute intravenous infusions, with MRI scans conducted prior to treatment and 8 days after the initial dose of JM-4.
Once safety is established in this cohort of patients, a third group of patients may receive 9 mg/kg/ of JM-4 daily for 5-7 days via 30 minute infusions, with MRI scans conducted prior to the initial treatment and 8 days after the initial treatment.
Study Type
Interventional
Enrollment (Anticipated)
15
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Stuart Cook, MD
- Phone Number: (201) 213-5052
- Email: cookstu@comcast.net
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Definite MS (McDonald criteria) or CIS
- GAD(+) MRI brain lesion on screening exam, with or without clinical activity followed by a baseline MRI
- EDSS of 0-5.5 inclusive
- Weight of 40-115 kg
- Females must be post-menopausal or surgically sterilized or use a hormonal contraceptive, intra-uterine device or diaphragm with spermicide during the study
- Not be pregnant or breast feeding
- Males must be willing to use contraception during each day of the study
- Be willing to comply with study procedures and protocols for the duration of the study
- Voluntarily provide informed consent
- Be wiling and physically able to attend the study center as required for all study screening and procedures
Exclusion Criteria:
- Taking Tysabri, Gilenya, Tecfidera, Aubagio, Ocrevus or other immunosuppressive drugs within the prior 3 months
- Received Mitoxantrone or Lemtrada at any time
- Consumption of corticosteroids within the past 30 days
- Current or less than 5 years prior malignancy (excluding basal cell or squamous cell skin cancer)
- Serious systemic disorder which might, in the opinion of the investigators, interfere with safety, compliance, treatment or evaluation of efficacy. Conditions would include but not be limited to significant cardiac, liver, kidney, lung or cerebrovascular disease, HIV, serious infections, serous psychiatric disease or poorly controlled diabetes mellitus
- aversion, intolerance or allergy to repeated MRI with gadolinium administration
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Starting dose
Three to five patients will receive a daily dose of 1 mg/kg JM-4 (in normal saline) delivered via intravenous infusion for no more than 30 minutes for up to 7 consecutive days.
|
Novel small human peptide derived from erythropoietin
|
Experimental: Intermediate dose of JM-4
Three to five patients will receive a daily dose of 4 mg/kg of JM-4 (in normal saline) via intravenous infusion for no more than 30 minutes for up to 7 consecutive days.
|
Novel small human peptide derived from erythropoietin
|
Experimental: High dose of JM-4
Three to five patients will receive a daily dose of 9 mg/kg of JM-4 (in normal saline) via intravenous infusion for no more than 30 minutes for up to 7 consecutive days.
|
Novel small human peptide derived from erythropoietin
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients with treatment-related adverse events
Time Frame: From initial dose through 8 days after initiation of dosing
|
To determine the incidence of adverse events and any abnormal laboratory values
|
From initial dose through 8 days after initiation of dosing
|
Change in GAD(+) brain lesions measured via MRI scan
Time Frame: From initial dose through 8 days after initiation of dosing
|
Measurement of the number and size of GAD(+) brain lesions from baseline to post-dosing 8 days after initiation of treatment
|
From initial dose through 8 days after initiation of dosing
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in the ability of patients to complete a timed 25-foot walk
Time Frame: From initial dosing through 8 days post-initiation of dosing
|
To determine changes in timed 25 foot walk prior to treatment or 8 days after treatment
|
From initial dosing through 8 days post-initiation of dosing
|
Treatment-induced changes in Expanded Disability Status Score in patients
Time Frame: Prior to initial dose through 8 days post-initial treatment
|
Measurement of Expanded Disability Status scores in patients prior to treatment and after completion of treatment
|
Prior to initial dose through 8 days post-initial treatment
|
Changes in neurological exam
Time Frame: Prior to initial dose through 8 days post-initial treatment
|
Neurological examination of patients to check for optic nerve changes and vision changes
|
Prior to initial dose through 8 days post-initial treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Stuart Cook, MD, VA Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
June 15, 2019
Primary Completion (Anticipated)
December 15, 2019
Study Completion (Anticipated)
March 15, 2020
Study Registration Dates
First Submitted
March 10, 2019
First Submitted That Met QC Criteria
March 21, 2019
First Posted (Actual)
March 22, 2019
Study Record Updates
Last Update Posted (Actual)
May 7, 2019
Last Update Submitted That Met QC Criteria
May 5, 2019
Last Verified
March 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- JM-4-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
Brigham and Women's HospitalMassachusetts General HospitalRecruitingMultiple Sclerosis | Relapsing Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
University of MinnesotaMallinckrodtTerminatedPrimary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
Clinical Trials on JM-4
-
Contera PharmaBukwang PharmaceuticalActive, not recruitingDyskinesiasFrance, Germany, Italy, Korea, Republic of, Spain
-
Western University, CanadaRecruitingOsteoarthritis | Osteo Arthritis Knee | Hip ArthritisCanada
-
Draeger Medical Systems, Inc.CompletedHyperbilirubinemia | Neonatal JaundiceCanada
-
Norwegian University of Science and TechnologyCompletedInfant, Very Low Birth WeightNorway
-
Bukwang PharmaceuticalActive, not recruitingParkinson Disease | DyskinesiasUnited States
-
Imam Abdulrahman Bin Faisal UniversityUnknownDiabetic Foot | Plantar FasciitisSaudi Arabia
-
Bukwang PharmaceuticalContera Pharma ApSCompletedParkinson's Disease | Levodopa Induced Dyskinesia (LID)South Africa
-
Pharma Holdings ASCTC Clinical Trial Consultants ABCompletedNasal Decolonization of Staphylococcus AureusSweden
-
Janssen Research & Development, LLCCompleted